Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 35


Patients' expectations about effects of chemotherapy for advanced cancer.

Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D.

N Engl J Med. 2012 Oct 25;367(17):1616-25. doi: 10.1056/NEJMoa1204410.


Bending the cost curve in cancer care.

Smith TJ, Hillner BE.

N Engl J Med. 2011 May 26;364(21):2060-5. doi: 10.1056/NEJMsb1013826. No abstract available.


[Psychological comorbidity in patients with cancer].

Weis J, Boehncke A.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jan;54(1):46-51. doi: 10.1007/s00103-010-1184-y. German.


Fatigue in cancer: a review of literature.

Narayanan V, Koshy C.

Indian J Palliat Care. 2009 Jan;15(1):19-25. doi: 10.4103/0973-1075.53507.


Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR.

J Clin Oncol. 2009 Aug 1;27(22):3677-83. doi: 10.1200/JCO.2008.20.5278. Epub 2009 May 26.


Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.

Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.


Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.


Illness-related hopelessness in advanced cancer: influence of anxiety, depression, and preparatory grief.

Mystakidou K, Tsilika E, Parpa E, Athanasouli P, Galanos A, Anna P, Vlahos L.

Arch Psychiatr Nurs. 2009 Apr;23(2):138-47. doi: 10.1016/j.apnu.2008.04.008. Epub 2008 Oct 15.


Patient attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancer.

Chu DT, Kim SW, Hsu HK, Cok G, Roubec J, Patil S, Damyanov D, West T, Hall B, Altug S.

Lung Cancer. 2009 Nov;66(2):250-6. doi: 10.1016/j.lungcan.2009.01.022. Epub 2009 Mar 4.


Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment.

Wright AA, Zhang B, Ray A, Mack JW, Trice E, Balboni T, Mitchell SL, Jackson VA, Block SD, Maciejewski PK, Prigerson HG.

JAMA. 2008 Oct 8;300(14):1665-73. doi: 10.1001/jama.300.14.1665.


Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R.

N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.


Evidence-based recommendations for information and care planning in cancer care.

Walling A, Lorenz KA, Dy SM, Naeim A, Sanati H, Asch SM, Wenger NS.

J Clin Oncol. 2008 Aug 10;26(23):3896-902. doi: 10.1200/JCO.2007.15.9509. Review.


Palliative chemotherapy preferences and factors that influence patient choice in incurable advanced cancer.

Kim MK, Lee JL, Hyun MS, Do YR, Song HS, Kim JG, Bae SH, Ryoo HM, Park KU, Lee KH.

Jpn J Clin Oncol. 2008 Jan;38(1):64-70. doi: 10.1093/jjco/hym147. Epub 2008 Jan 31.


Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom.

N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149.


Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.


Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group.

J Clin Oncol. 2006 Nov 1;24(31):4991-7.


Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health.

Health Qual Life Outcomes. 2006 Oct 11;4:79.


Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer.

Matsuyama R, Reddy S, Smith TJ.

J Clin Oncol. 2006 Jul 20;24(21):3490-6. Review.


Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE.

J Clin Oncol. 2006 Jun 20;24(18):2903-9. Review.


Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences.

Olver IN, Taylor AE, Whitford HS.

Psychooncology. 2005 Jan;14(1):25-33.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk